We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

32 hedge funds and large institutions have $51.3M invested in Trillium Therapeutics Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 5

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

86% more capital invested

Capital invested by funds: $27.6M → $51.3M (+$23.7M)

10% more funds holding

Funds holding: 29 → 32 (+3)

Holders
32
Holders Change
+3
Holders Change %
+10.34%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$2.32M
2
PCA
Private Capital Advisors
Connecticut
+$1.69M
3
ACA
Avoro Capital Advisors
New York
+$1.01M
4
EAM
EverPoint Asset Management
Connecticut
+$967K
5
PC
Polar Capital
United Kingdom
+$380K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.12M
2
OAM
Oxford Asset Management
United Kingdom
-$905K
3
OM
Opaleye Management
Massachusetts
-$230K
4
KPF
K2 Principal Fund
Ontario, Canada
-$131K
5
TC
TFS Capital
Pennsylvania
-$107K
Name Holding Trade Value Shares
Change 		Change in
Stake
JHIU
1
Janus Henderson Investors US
Colorado
$8.42M +$34.3K +2,977 +0.5%
BBA
2
Baker Bros. Advisors
New York
$6.12M +$2.32M +201,905 +95%
Franklin Resources
3
Franklin Resources
California
$5.84M – – –
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$5.46M – – –
ACA
5
Avoro Capital Advisors
New York
$4.67M +$1.01M +87,323 +38%
EAM
6
EverPoint Asset Management
Connecticut
$4.43M +$967K +84,000 +39%
OM
7
Opaleye Management
Massachusetts
$2.59M -$230K -20,000 -10%
DM
8
Deerfield Management
New York
$2.55M – – –
PCA
9
Private Capital Advisors
Connecticut
$2.17M +$1.69M +146,633 New
SFM
10
Sphera Funds Management
Israel
$1.96M – – –
CS
11
Candriam SCA
Luxembourg
$1.63M – – –
PI
12
Putnam Investments
Massachusetts
$1.48M – – –
NLVP
13
New Leaf Venture Partners
New York
$1.19M – – –
PC
14
Polar Capital
United Kingdom
$488K +$380K +33,000 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$372K +$290K +25,170 New
ECM
16
Endurant Capital Management
California
$361K -$33.4K -2,900 -11%
FAM
17
Fred Alger Management
New York
$340K +$265K +23,000 New
SSA
18
Schonfeld Strategic Advisors
New York
$296K – – –
Millennium Management
19
Millennium Management
New York
$254K -$1.12M -97,286 -85%
OAM
20
Oxford Asset Management
United Kingdom
$247K -$905K -78,574 -82%
Wells Fargo
21
Wells Fargo
California
$175K +$124K +10,800 +1,080%
Creative Planning
22
Creative Planning
Kansas
$120K +$25.3K +2,200 +37%
Deutsche Bank
23
Deutsche Bank
Germany
$66K +$22.8K +1,977 +76%
TRCT
24
Tower Research Capital (TRC)
New York
$21K +$8.57K +744 +248%
SEI Investments
25
SEI Investments
Pennsylvania
$7K – – –
1
2

TRIL Hedge Fund Activity: Q3 2016 in Review

32 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2016, worth a combined $51.3M — up 86% from $27.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TRIL positions and 2 closed out — a net gain of 3 holders — while 13 added to existing stakes and 5 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $2.32M. The largest seller was Millennium Management, cutting an estimated $1.12M.

  • 32 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2016, up from 29 in Q2 2016.
  • Funds reported $51.3M of Trillium Therapeutics Inc. stock for Q3 2016, up 86% quarter-over-quarter.
  • 5 funds opened new Trillium Therapeutics Inc. positions in Q3 2016 and 2 closed out, a net change of +3 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q3 2016 was Baker Bros. Advisors, an estimated $2.32M added.
  • The largest Trillium Therapeutics Inc. seller in Q3 2016 was Millennium Management, an estimated $1.12M sold.

Based on aggregated 13F filings for Q3 2016.